High titer adeno-associated virus (AAV) production that is Cost-effective and Scalable скачать в хорошем качестве

High titer adeno-associated virus (AAV) production that is Cost-effective and Scalable

Presented By: Chao Yan Liu Speaker Biography: Chao Yan Liu, is a Senior Staff Scientist, at Cell Biology of the Life Sciences Solutions Group - now part of Thermo Fisher Scientific - at the Frederick (MD - USA) location. She received the M.D. degree from the Hebei Medical University (Hebei, China) and the Master degree in Pathology from the Academy of Military Medical Sciences in Beijing, China. After being very active for more than ten years in academic research in the field of cellular biology and immunology, in 2005 she joined the Research and Development department of the former Life Technologies. She has made great contributions to more than ten of the Gibco brand Cell Culture Essential products including AlgiMatrix 3D Culture System, OpTmizer CTS T-Cell Expansion SFM, TrypLE Select Enzyme, ES Cell Qualified FBS, GlutaMAX media supplement, FreeStyle F17 Expression Medium and CD FortiCHO Medium. She has extensive experiences in mammalian cell culture, serum and protein free, chemical defined medium formation as well as protein expression. In the past five years, she served as leading scientist to focus on the development of two novel transient transfection systems, Expi293™ and ExpiCHO Expression Systems. 公司细胞生物学部门的高级研究员，在美国马里兰州弗雷德里克工作。Chao Yan Liu女士拥有河北医科大学的医学学士学位和军事医学科学院的病理学硕士学位，先后在威斯康辛州血液中心的血液研究所以及纽约州立大学水牛城分校从事细胞生物学和免疫学领域的学术研究工作。Chao Yan Liu女士于2005年加入原Life Technologies公司研发部，对Gibco™ 品牌下十余款细胞培养产品的研发做出了卓越贡献，包括AlgiMatrix™ 3D培养系统、OpTmizer™ CTS™ T细胞扩增无血清培养基、TrypLE™ Select酶、适用于胚胎干细胞的FBS、MesenPRO RS™ 细胞培养基、GlutaMAX™ 培养基添加剂、FreeStyle™ F17表达培养基和CD FortiCHO™ 培养基，在哺乳动物细胞培养，尤其是化学成分确定的无血清和无蛋白培养以及重组蛋白表达方面积累了丰富的经验。最近五年，她作为瞬时蛋白表达课题研发的技术负责人致力于两种新型哺乳动物瞬时蛋白表达系统--Expi293™和ExpiCHO™的研究开发并取得了突破性进展。 Webinar: High titer adeno-associated virus (AAV) production that is Cost-effective and Scalable Webinar Abstract: Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs. AAV has an efficacy and safety profile that makes it an ideal therapeutic vector—already part of several high-profile drug approvals in both the US and Europe. Yet, with this intensified interest in AAV therapies comes the need to scale-up viral production methods. As such, it’s imperative that successful viral production produce high titers that is cost-effective and scalable. During this webinar session, our presenter will highlight a scalable, high-titer, simplified AAV production in the AAV-MAX helper free AAV Production System. LabRoots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc